Align Technology Collaborates on Switzerland's First Oral Health Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy ALGN?
Source: Businesswire
- Launch of Swiss Oral Health Study: Align Technology collaborates with the University of Bern on Switzerland's first oral health study, aiming to examine approximately 1,800 children by June 2026 and 1,650 adults by the end of 2027, providing crucial data for future public health strategies.
- Innovative Mobile Dental Van: The Align-branded mobile dental van equipped with the iTero Lumina scanner will travel to schools and communities across Switzerland, enhancing data collection efficiency while ensuring a comfortable experience for participants, particularly children.
- Enhanced Diagnostic Capabilities: The iTero Lumina scanner utilizes multi-angle capture and near-infrared imaging technology to scan the internal structure of teeth in real-time, aiding in the detection and monitoring of carious lesions, which is expected to significantly improve the accuracy of oral health assessments.
- Collaboration Between Academia and Industry: Align's involvement not only enhances data quality but also showcases the potential of collaboration between academia and industry to drive the application of digital diagnostic technologies, ultimately improving oral health outcomes for future generations.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALGN
Wall Street analysts forecast ALGN stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 172.730
Low
169.00
Averages
198.70
High
220.00
Current: 172.730
Low
169.00
Averages
198.70
High
220.00
About ALGN
Align Technology, Inc. is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad computer-aided design and computer-aided manufacturing (CAD/CAM) software for digital orthodontics and restorative dentistry. The Company provides Align Digital Platform. Its segments include Clear Aligner, and Imaging Systems and CAD/CAM Services (Systems and Services). The Clear Aligner segment consists of comprehensive products, non-comprehensive products and non-case products. Its comprehensive products include Invisalign Comprehensive and Invisalign First. The Company's non-case products include retention products, Invisalign training and adjusting tools. It offers up to four sets of custom clear aligners called Vivera retainers. The Systems and Services segment consists of its iTero intraoral scanning systems. Its services include subscription software, disposables, rentals, leases and pay per scan services.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Earnings Release Schedule: Align Technology announced it will report its Q1 2026 financial results on April 29, 2026, after market close at 4:00 p.m. ET, reflecting the company's commitment to transparent communication with stakeholders.
- Conference Call Details: Following the earnings release, Align will host a conference call at 4:30 p.m. ET to discuss the financial results, indicating the company's intent to enhance investor confidence through direct engagement and transparency.
- Product Overview: Align's Invisalign® system is the most advanced clear aligner system globally, serving approximately 295,600 doctor customers, showcasing its leadership in digital orthodontics and restorative dentistry.
- Market Opportunity: Align's products and services provide access to a 600 million consumer market opportunity, having treated around 22.1 million patients over the past 29 years, highlighting its ongoing innovation and market potential in digital dentistry.
See More
- Market Decline: On Thursday, the S&P 500 fell by 0.27%, the Dow Jones Industrial Average by 0.44%, and the Nasdaq 100 by 0.29%, indicating a broad market decline driven by inflation concerns and investor pessimism.
- Energy Price Volatility: Crude oil prices experienced significant fluctuations as WTI initially rallied before retreating after Israel's assistance to the US in opening the Strait of Hormuz, highlighting the direct impact of geopolitical tensions on energy markets.
- Rising Bond Yields: The 10-year German Bund yield rose to a 2.25-year high of 3.01%, while the 10-year US Treasury yield reached a 6.75-month high of 4.32%, reflecting market expectations of potential tightening monetary policies by central banks, which could increase borrowing costs.
- Economic Data Impact: US weekly initial jobless claims unexpectedly fell to 205,000, indicating a strong labor market, while the Philadelphia Fed business outlook survey unexpectedly rose to a 6-month high of 18.1, further intensifying market concerns over potential interest rate hikes.
See More
- Investor Stake Increase: Elliott Investment Management has become one of Align Technology's largest investors, indicating a strategic intent to push for stock price improvement and potentially engage with management to explore options for enhancing share value.
- Stock Price Decline: Align's stock has sharply fallen from its 2021 peak of $729.92 to a recent close of $172.41, reflecting a market value of approximately $12.3 billion, which highlights a significant drop in demand following a surge in cosmetic dental treatments during the pandemic.
- Signs of Market Stabilization: Barclays analysts noted in a February 4 report that dental markets may be finding a floor this year, suggesting that Align could recover some lost valuation, with potential trading closer to 12 times EBITDA compared to around 10 times currently, indicating possible upside.
- Historical Valuation Comparison: Although Align's valuation remains below historical averages of 17 and 21 times over three- and five-year periods, respectively, improving market conditions could yield higher returns for investors, particularly as factors related to its Israel manufacturing operations evolve.
See More
- Market Decline: The S&P 500 index fell by 0.43%, the Dow Jones Industrial Average by 0.59%, and the Nasdaq 100 by 0.44%, indicating a broad sell-off in global equities driven by inflation concerns and investor pessimism.
- Rising Bond Yields: Hawkish comments from the BOE, ECB, and BOJ pushed global bond yields higher, with the 10-year German Bund yield reaching a 2.25-year high of 3.01%, which will increase borrowing costs and impact corporate financing.
- Surging Energy Prices: European natural gas prices surged over 12% to a three-year high due to escalating conflict in Iran, with Qatar reporting a 17% damage to its LNG export capacity, raising inflation risks and potentially disrupting global energy supplies.
- Strong US Economic Data: Despite initial jobless claims unexpectedly falling to 205,000, indicating a robust labor market, January new home sales plummeted 17.6% to 587,000, below expectations, reflecting weakness in the housing market that may affect future economic growth.
See More
- Healthcare Index Decline: The NYSE Health Care Index fell by 0.4% on Thursday afternoon, indicating a decline in overall market confidence in the healthcare sector, which may influence investors' decisions regarding stock holdings.
- Market Sentiment Weakens: The drop in healthcare stocks may be linked to broader economic uncertainties, as investor concerns about future economic growth intensify, leading to capital outflows from the healthcare sector and impacting its short-term performance.
- Investor Reactions: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors that are performing better to mitigate risk and seek higher returns.
- Uncertain Industry Outlook: The future performance of the healthcare sector may be influenced by policy changes and market dynamics, prompting investors to closely monitor relevant policy developments to adjust their investment strategies accordingly.
See More
- Oil Price Surge Impact: Stocks fell as Brent crude briefly hit $119 per barrel following Iran's attack on a key LNG facility in Qatar, causing the S&P 500 to slip below its 200-day moving average for the first time since last May, raising concerns among long-term investors.
- Eli Lilly Drug Study Update: Eli Lilly reported that its Phase 3 study of retatrutide for type 2 diabetes showed superior weight loss compared to Mounjaro over 40 weeks, yet the stock remained stagnant as investors are more focused on the anticipated approval of its new GLP-1 pill next month.
- Nvidia Stock Analysis: Jim Cramer reiterated his
See More











